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Abstract: Aim: To characterize episodic breathlessness (EB) in patients with advanced cancer, and to
determine factors influencing its clinical appearance. Methods: A consecutive sample of advanced
cancer patients admitted to an acute palliative care unit was surveyed. Continuous dyspnea and EB
were measured by a numerical scale. The use of drugs used for continuous dyspnea and EB was
recorded. Patients were asked about the characteristics of EB (frequency, intensity, duration and
triggers). The Multidimensional dyspnea profile (MDP), the Brief dyspnea inventory (BDI), the Athens
sleep scale (AIS) and the Hospital Anxiety and Depression Scale (HADS) were also administered.
Results: From 439 advanced cancer patients surveyed, 34 and 27 patients had EB, without and with
background dyspnea, respectively. The mean intensity and the number of episodes were higher
in patients with background dyspnea (p < 0.0005 and p = 0.05, respectively). No differences in
duration were observed. Most episodes lasted <10 min. A recognizable cause triggering EB was
often found. The presence of both background dyspnea and EB was associated with higher values
of MDP and BDI. EB was independently associated with frequency and intensity of background
dyspnea (OR = 20.9, 95% CI (Confidence interval) 9.1–48.0; p < 0.0005 and OR = 1.97, 95% CI 1.09–3.58;
p = 0.025, respectively) and a lower Karnofsky level (OR = 0.96, 95%CI 0.92–0.98, p = 0.05). Discussion:
EB may occur in patients with and without continuous dyspnea, and is often induced by physical and
psychological factors. EB intensity is higher in patients with continuous dyspnea. The duration was
often so short that the use of drugs, as needed, may be too late, unless administered pre-emptively
when the trigger was predictable.
Keywords: dyspnea; episodic breathlessness; opioids; palliative care; advanced cancer
1. Introduction
Dyspnea is a very distressing symptom often reported in advanced cancer patients, particularly
in the last months of life [1]. Dyspnea is associated with relevant suffering, both in cancer patients and
caregivers. Although patients with lung cancer are commonly considered at higher risk to develop
dyspnea, this symptom may largely occur in other primary tumors [2]. Dyspnea has been defined as
an unpleasant sensation in or experience of breathing, characterized by qualitatively distinct sensations
presenting with variable intensity [3].
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Dyspnea is often a continuous phenomenon present for most hours of the day. However, this
symptom may also occur abruptly due to known and unknown triggering factors, or may aggravate
or overlap with the background condition, with peaks of intensity clearly distinguishable from the
background level, resembling the phenomenon of breakthrough cancer pain [4]. This phenomenon
is commonly named episodic breathlessness (EB) [5]. On the other hand, EB may develop without
significant background dyspnea, mainly due to the activation of triggering factors.
In the last few years, EB has been differently characterized, and more information is now available.
As EB is a complex entity demanding complex management, it is of paramount importance to gather
data about this phenomenon in order to optimize the treatment and to provide better and individualized
therapeutic options [5–9].
In previous papers, the prevalence of dyspnea and EB were surveyed in advanced cancer patients
recruited in different settings. However, the selection of patients was based on the presence of
background dyspnea. Moreover, only physical factors were taken into consideration, excluding
possible psychological factors as triggering agents for EB [8,9]. The aim of this study was to better
characterize EB, in the presence or not of background dyspnea. The secondary outcome was to explore
factors that may influence its clinical appearance.
2. Patients and Methods (Ethical Code: n.1/2014)
A consecutive sample of advanced cancer patients admitted to an acute palliative care unit was
surveyed for a period of 18 months. This unit is characterized by the admission of patients who often
receive anticancer therapies and require pain and symptom management. Thus, this cohort of cancer
patients are admitted in a relatively early stage of disease, and in some cases are admitted before
staring a treatment. The activities of this unit have been described elsewhere [10].
Inclusion criteria were age ≥18 years, a diagnosis of cancer, and the ability to provide information
about continuous dyspnea and EB. Exclusion criteria were the incapacity to complete the questionnaires
for any reason, relevant cognitive failure (Memorial Delirium Assessment Scale (MDAS) ≥13, on a
scale 0–30), any refusal, and a Karnofsky level of ≤20 (on a scale 0–100). Patients’ informed consent
and institutional approval from the University of Palermo were obtained.
2.1. Data Collection
At-admission age, gender, primary tumor, Karnofsky level, stage of disease, concomitant
comorbidities and oncologic treatments were recorded. Patients meeting inclusion and exclusion
criteria were asked about the presence of any form of dyspnea. If the answer was yes, assessment
was continued. The palliative prognostic score (PaP) was calculated. The PAP uses the Karnofsky
Performance Score (KPS) and five other criteria to generate a numerical score from 0 to 17.5 (higher
scores predicting shorter survival) [11]. Continuous dyspnea, defined as a sensation of breathlessness
for most hours of the day, was measured by the Edmonton Assessment Symptom scale (ESAS) over the
previous 24 h. The ESAS consists of 10 items, including dyspnea, which are rated 0 to 10, evaluating
the intensity of physical and psychological symptoms and the sense of poor well-being [12]. The use of
drugs for continuous dyspnea was recorded.
The definition of EB was made according to an agreement among experts, and included: the
intermittent, time-limited character of episodes; the subjective experience and qualitative aspects of
breathing discomfort that differentiate episodic from continuous breathlessness in general; and
predictability (triggered by identifiable factors) [7]. Patients were asked about the number of
episodes/day (clearly distinguished from baseline dyspnea, if any), intensity, and duration of untreated
episodes. Other information included the eventual triggers (physical activity, going upstairs, walking,
movement in the bed, supine position), if dyspnea hindered every day and favorite activities, or these
activities did not solve it or prevent it, if anxiety induced EB and vice versa (if EB induced anxiety),
and daily prevalence (diurnal or nocturnal) of EB. Information on drugs used for continuous dyspnea
and EB, and their efficacy (effective, moderately effective, ineffective), were collected.
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2.2. Measurements
The Multidimensional dyspnea profile (MDP), the Brief dyspnea inventory (BDI), the Athens
sleep scale (AIS) and the Hospital Anxiety and Depression Scale (HADS) were administered. The MDP
is a tool developed to separately measure the immediate unpleasantness or discomfort of breathing,
the presence and intensity of five sensory quality items, and the intensity of five emotional responses
to breathlessness (for each item, the score is 0–10) [13,14]. The BDI is a valid and reliable measure for
evaluating dyspnea, and to inform about the relative severity and interference of dyspnea in daily life
activities (7 items, score 0–10) [15]. The AIS is a self-assessment psychometric instrument designed for
quantifying sleep difficulty. It consists of eight items: the first five items pertain to sleep induction,
awakenings during the night, final awakening, total sleep duration and sleep quality; while the last
three refer to well-being, functioning capacity and sleepiness during the day [16]. Each item is scored
from 0 to 3. The HADS is a self-assessment tool and consists of 14 items, with two separate subscales
for anxiety and depression. The total score ranges from 0 to 42, with a higher score indicating severe
depression and anxiety [17].
2.3. Statistical Analysis
Summary statistics for dyspnea, continuous and categorical variables, and the associated
frequency distributions have been provided. Primary tumors have been categorized into 12 categories.
The variable age has been categorized, to improve its interpretability and model implementation, into
four categories, ranging from an age less than 66 years to an age more than 85 years. Categorical
variables were described as absolute (n) and relative (%) frequencies; mean and standard deviation
(SD) summarized the continuous variables. χ2 explorative cross-tabulation tests of association among
variables, assuming α = 0.05, were carried out.
Differences between the clinical characteristics of patients with dyspnea and EB dyspnea were
assessed by the chi-square test or Fisher exact test, as needed for categorical variables, and by
the independent Student t test for continuous parameters if the data were normally distributed.
The differences between time intervals were determined via paired t-test.
All variables that were found to be significantly associated (p ≤ 0.05) in the univariate analysis
were included in a multivariate regression model. Data were analyzed by IBM SPSS Software
22 version (IBM Corp., Armonk, NY, USA). All p-values were two-sided and p < 0.05 was considered
statistically significant.
3. Results
A total of 439 advanced cancer patients admitted to the acute pain relief and supportive/palliative
care unit were surveyed in the study period. Of the initial patients screened, 40 patients reported
background dyspnea. One patient was then excluded for inability to provide further data. The mean
Karnofsky status recorded at admission was 51.3 (SD = 9.5). The characteristics of patients are shown
in Table 1. Lung cancer, bronchopulmonary diseases and palliative care treatment were statistically
associated with dyspnea. The mean values of ESAS items (SD) are reported in Table 2.
A total of 74 patients reported background dyspnea, EB, or both. In total, 38 (8.7%), 26 (5.9%) and
4 (0.9%) patients belonged to PaP risk groups A, B and C, respectively (data were missing for some
patients). Of the 40 patients with background dyspnea, 27 (67.5%) had EB. A total of 34 patients had
EB without reporting background dyspnea (Figure 1).
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≤65 years 200 (93.5%) 14 (6.5%)
p = 0.18966–75 years 129 (88.4%) 17 (11.6%)
76–85 years 59 (86.8%) 9 (13.2%)
≥85 years 7 (100%) 0 (0%)
Gender
Male 207 (91.6%) 19 (8.4%) p = 0.621
Female 191 (90.1%) 21 (9.9%)
Cancer
Lung 75 (75.8%) 24 (24.2%)
p < 0.0005
Breast 46 (88.5%) 6 (11.5%)
Gastrointestinal 101 (98.1%) 2 (1.9%)
Liver 15 (100%) 0 (0%)
Gynecological 22 (91.7%) 2 (8.3%)
Head-Neck 14 (87.5%) 2 (12.5%)
Haematological 7 (100%) 0 (0%)
Prostate 17 (100%) 0 (0%)
Pancreas 47 (100%) 0 (0%)
Urological 25 (92.6%) 2(7.4%)
Other 25 (92.6%) 2 (7.4%)
Unknown 4 (100%) 0 (0%)
Comorbidity
Cardiovascular
Yes 188 (88.7%) 24 (11.3%) p = 0.166
No 174 (93.0%) 13 (7.0%)
Bronco-pulmunary Yes 33 (75.0%) 11 (58.0%) p = 0.010
No 329 (89.9%) 37 (10.1%)
Kidney disease Yes 12 (85.7%) 2 (14.3%) p = 0.379
No 350 (90.9%) 35 (9.1%)
Liver disease
Yes 9 (100%) 0 (62.5%) p = 1.0
No 353 (90.5%) 37 (9.5%)
None 120/398 (30.2%) 6/40 (15.0) p = 0.032
Treatment
Disease-oriented 264 (92.6%) 22 (7.4%) p = 0.165
Palliative Care 6 (22.2%) 21 (77.8%) p = <0.0005









Poor sleep 4.41 3.426
Poor appetite 4.41 3.646
Poor well-being 5.43 2.798
Total 43.87 16.996
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Figure 1. Flo chart of patients’ distribution. .
3.1. Background Dyspnea
The prevalence of background dyspnea was 9.1% (40/839). In such patients, the mean intensity of
dyspnea was 5.9 (SD 2.1). A total of 22 patients (55%) were receiving drugs for background dyspnea, in
the rank order corticosteroids (n.10, 25%), bronchodilatators (n.5, 12.5%), oxygen (n.3, 7.5%), diuretics
(n.2, 5%) and opioids (n.1, 2.5%). Associated comorbidities (n = 34, 85%) were in the rank order
cardiovascular disease (70.6%), chronic obstructive pulmonary disease (32.3%), renal failure (5.9%),
and others (52.9%).
Background dyspnea was significantly associated with cancer diagnosis (>in lung cancer, p < 0.0005,
Fisher’s exact test, <in gastrointestinal and pancreatic cancer, p = 0.003 and p = 0.014, respectively;
Fisher’s exact test), comorbidities (bronchopulmonary, p = 0.010, Fisher’s exact test) and type of
treatment (palliative care, p < 0.0005, Fisher’s exact test) (Table 1). According to the multinomial logistic
regression analysis, the risk of background dyspnea increased with the diagnosis of lung cancer (OR
1.14, 95%CI 1.02–1.27, p = 0.019).
3.2. Episodic Breathlessness
In total, 34 patients and 27 patients had EB without and with background dyspnea, respectively.
The mean intensities of EB were 5.8 (SD 2.2) and 7.7 (SD 1.8) in patients without and with background
dyspnea, respectively. The difference was statistically significant (p < 0.0005, t-test). The mean number
of episodes/day was 3.4 (SD 2.3, range 1–15). The number of episodes was significantly higher in
patients with background dyspnea (p = 0.05).
In the 27 patients with background dyspnea, the mean durations of EB were <5 min, 5–10, 11–20
and >20 min in 14, 6, 5 and 1 patients, respectively (data missing for one patient). In the 34 patients
without background dyspnea, the mean durations of EB were <5 min, 5–10, 11–20 and >20 min, in
17, 8, 2 and 5 patients, respectively (missing data for 2 patients). The difference was not significant
(p = 0.267, chi square test).
In all patients, a recognizable cause triggering EB was found, as follows: going up the stairs
(n = 35), walking (n = 44), movement in the bed (n = 18), supine position (n = 16) and psychological
factors (anxiety, panic) (n = 46). In 43 patients, EB upon movement limited or prevented daily activities.
In 27 patients, anxiety induced EB, while in 32 patients EB induced anxiety. Finally, in 19 patients
the influence was reciprocal. EB prevalence was diurnal, nocturnal or both, in 31, 11 and 18 patients,
respectively. In total, 17 patients were receiving drugs for EB, including bronchodilatators (n = 7),
corticosteroids (n = 4), oxygen (n = 3), diuretics (n = 1) and others (n = 2). The efficacy was high, mild
and poor in 1, 9 and 3 patients, respectively.
The mean MDP was 6.1 (SD 2.4) for muscle effort; 6.7 (SD 2.3) for unpleasantness; 24.1 (SD 11)
for quality-intensity, and 20.1 (SD 14.2) for emotional responses to dyspnea. The mean BDI was 38.2
(SD 15.6). The mean ASS was 9.1 (SD 4.7). The mean HADS-A was 8.9 (SD 4.1). The mean HADS-D
was 9.6 (SD 3.9), while HADS total was 18.5 (SD 6.6).
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The differences in MDP items, ASS, HADS-A, HADS-D and total HADS, in patients with
background dyspnea, background dyspnea and EB, and EB alone, are reported in Table 3. Patients
with background dyspnea and EB had the highest values of MDP items and BDI.
Table 3. Differences in MDP items, ASS, HADS-A, HADS-D, and total HADS (see text) in patients with




EB (27 pts) EB Only (34 pts)
Mean SD Mean SD Mean SD
MDP effort 3.83 3.433 7.16 1.818 5.29 2.452 0.0003 A vs. B0.002 C vs. B
MDP
unpleasantness 4.50 2.876 7.69 1.463 5.84 2.541
<0.0005 A vs. B
0.001 C vs. B
MDP
quality-intensity 18.17 14.534 27.40 8.124 21.53 12.371
0.014 A vs. B
0.038 C vs. B
MDP emotional 15.33 13.255 22.00 14.547 18.55 13.994 NS
BDI 32.58 15.635 42.70 11.671 34.19 17.610 0.027 A vs. B0.035 C vs. B
ASS 9.17 5.006 9.81 3.962 8.59 5.200 NS
HADS-A 8.20 3.458 9.00 4.287 8.88 3.951 NS
HADS-D 8.20 2.658 8.91 3.146 10.12 4.512 NS
TOTAL HADS 16.40 5.680 17.91 6.886 19.00 6.468 NS
In the univariate analysis, EB was associated with the frequency (p < 0.0005) and intensity of
background dyspnea (p = 0.007), a diagnosis of lung cancer (p < 0.0005), a lower Karnofsky level
(p = 0.020), bronchopulmonary comorbidities (p = 0.045), palliative care treatment (p < 0.0005),
MDP effort (p = 0.007) and MDP unpleasantness (p = 0.006). In the multivariate analysis, EB was
independently associated with frequency and intensity of background dyspnea (OR = 20.9, 95%CI
9.1–48.0; p < 0.0005 and OR = 1.97, 95%CI 1.09–3.58; p = 0.025, respectively) and a lower Karnofsky
level (OR = 0.96, 95%CI 0.92–0.98, p = 0.05).
4. Discussion
The principal findings of this study were that patients may develop EB with or without background
dyspnea, and that patients having background dyspnea or a lower Karnofsky status developed more,
and more severe, EB episodes. EB was often induced by physical and psychological factors. Of interest,
the prevalence of background dyspnea was low in this cohort of patients.
4.1. Background Dyspnea
A lower prevalence of background dyspnea (less than 10%) was found in comparison with the
previous data reported in the literature, which possibly depended on different stages of disease and
settings [1,2,18,19]. In home palliative care patients, presumably having a short life expectancy, the
prevalence of dyspnea was about 35%, and the Karnofsky level was noticeably lower [19]. In another
study performed in inpatients and outpatients, constant dyspnea accounted for 39% of subjects who had
a median Karnofsky of 80. Of these patients, 20% also experienced episodes of EB [20]. This difference
could be due to the different settings and methodologies. This data suggests that patients included
in this analysis were admitted early in the course of their disease, according to the characteristics of
this unit previously described [10], as confirmed by the relatively higher level of Karnofsky status
recorded at admission. The second point regarding chronic dyspnea was that opioids were given
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to only one patient. Opioids are often given in more advanced stages of disease, although the best
evidence supports the use of opioids for breathlessness in opioid-naïve patients [18].
As expected, some factors, such as lung cancer, chronic respiratory disease and no anticancer
treatment, were found to be associated with background dyspnea, although only lung cancer was
independently associated with background dyspnea.
4.2. Episodic Breathlessness
Of the 40 patients with background dyspnea, 27 (67%) experienced EB episodes, while 37 patients
experienced EB alone. In a previous study, continuous dyspnea accounted for 27 (39%) patients,
and among them 14 (20%) patients also presented episodes of EB. EB alone occurred in 43 (61%) of
patients [20]. A similar categorization has been proposed, adding further elements of complexity
when evaluating EB [7]. Of interest, more episodes were reported in patients with background
dyspnea, resembling patients with breakthrough pain, wherein pain episodes are more likely to occur
in patients with higher levels of background pain [4]. This observation also supports the optimization
of background dyspnea with an appropriate treatment, possibly anticipating the use of opioids.
This aspect deserves future studies.
4.3. Triggers for Episodic Breathlessness
In different chronic lung diseases, EB on movement limited or prevented the daily activity. EB
triggered by exertion, non-triggered EB and continuous dyspnea have been found to be the most
frequent and important categories, with a high impact on daily living. Exertional EB occurred in
nearly all patients [5,6]. Similar to other studies [7,20], EB prevalence was prevalently distributed
during the day, although episodes also occurred at night, when physical activity is commonly minimal.
Many episodes were triggered by psychological factors. This aspect has not been explored in previous
studies [8,9], and has not been specifically assessed in other studies. Of interest, anxiety may circularly
be produced by the EB episode itself. Similar to EB induced by physical activity, the preventive use of
anxiolytics around the clock, or non-pharmacologic techniques, may be helpful in preventing episodes
triggered by fear or panic. These aspects deserve further exploration.
4.4. Episodic Breathlessness Intensity
EB intensity in patients with background dyspnea was shown to be higher than in patients without
dyspnea. This finding has never been reported in previous studies, in which a mean intensity of 6.5
was reported, regardless of the background dyspnea intensity [20,21]. This can be explained by the
level of tolerance expressed by these patients, who are likely to require higher levels of EB intensity to
feel a clear difference from their baseline dyspnea.
4.5. Episodic Breathlessness Duration
From a clinical perspective, EB duration has an obviously relevant role. Most events lasted less
than 5 min, and 78% of patients reported an EB duration of ≤10 min, with no differences between
patients with or without continuous dyspnea. This data is consistent with previous experiences in
patients with different diseases, in which an EB duration of less than 10 min was found in 75–88% of
cases, the majority being less than 5 min [20–22], and with only 9% of episodes lasting more than 20 min.
The short duration of EB refers us back the therapeutic options, commonly based on the administration
of drugs like opioids, with a short onset. It is hard to argue that there would be a treatment effective in
such a short time. In a randomized, placebo-controlled, double-blind, double-dummy study, small
doses of nebulized hydromorphone, systemic hydromorphone and nebulized saline in opioid-tolerant
patients did not differ in their ability to improve EB 10 min after administration, although a clinical
improvement of at least one point was achieved with nebulized hydromorphone. Breathlessness scores
decreased linearly from 10 to 60 min post-treatment completion [23]. In a randomized cross-over study
performed in a real-life clinical setting, focused on exertional EB, the mean times to onset for fentanyl
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buccal tablet and oral morphine were 12.7 and 23.6 min, respectively [24]. Considering that about 80%
of episodes last ≤10 min, it is likely that the effect is produced by the natural course of EB, with a
spontaneous disappearance, particularly when EB is induced by an effort, possibly stopped after EB
occurred [25].
It seems evident that a better option would be the pre-emptive use of drugs, like short-onset
opioids, for predictable events, rather than a treatment once the episode occurred, as most episodes
will vanish before any treatment can provide a clinical effect. This is confirmed by the finding
that most episodes were triggered by predictable physical efforts. A series of studies demonstrated
that walking-induced EB may be reduced by the prophylactic use of transmucosal or subcutaneous
fentanyl, which demonstrated a dose–response relationship in improving both dyspnea and walking
distance [26–29]. Of interest, the high-dose groups (35–45% of the daily background equivalent opioid
dose) were more likely to report at least somewhat better improvement, without producing significant
adverse events, confirming the protective role of the level of opioid tolerance reported for breakthrough
pain [4]. Considering that oral opioids take about 30 min, and fast-acting drugs about 10 min, to
provide a clinical effect, these options could be inappropriate for these short-lasting episodes, unless
used pre-emptively, before a predictable effort. Nonpharmacological strategies (e.g., panic control
techniques, distraction or hand-held fan) could be accessible at any time, and might be helpful. Patients
may use a number of different strategies to cope with EB, including a reduction of physical exertion, a
change of position, laying down flat or standing up and raising the hands, environmental strategies,
concentrating on the breathing or distracting from any thoughts of breathlessness, breathing techniques,
air and oxygen, or cognitive and psychological strategies [30]. However, these strategies need more
specification and an appropriate clinical evaluation for the management of EB.
4.6. Factors Associated with Continuous Dyspnea and Episodic Breathlessness
No differences were found for patients with sleep disturbances or psychological factors, assessed
by ASS and HADS, among the categories of dyspnea with EP, without EB and EB alone. Indeed, patients
with both background dyspnea and EB had the highest values of MDP items and BDI. This finding
suggests that the unpleasantness or discomfort of breathing, the presence and intensity of sensory
quality items, emotional responses to breathlessness, and interference in daily life activities are more
likely to develop in this category of patients. Thus, this group of patients develops the greatest global
burden, compared to patients with EB or background dyspnea alone. In a previous study performed on
patients with cardiopulmonary diseases, severity and unpleasantness were found to be associated with
worse perceived quality of life, age, gender, diagnosis, morning/evening assessment, breathlessness
score, morphine treatment and the presence of different sensory qualities of breathlessness [14].
The principal limitation of this study involves the specific characteristics of the acute palliative
care unit, where only cancer patients are admitted, relatively early for palliative care, and for different
reasons. This explains the low number of patients with dyspnea who were recruited, in comparison with
the prevalence of dyspnea observed in other studies. The explorative design limits the generalization
of our results. No sample size was calculated beforehand and the categories tested were built post hoc.
Therefore, the present results need to be interpreted with caution.
5. Conclusions
EB may occur in patients with and without continuous dyspnea, and it is often induced by physical
and psychological factors. EB intensity is greater in patients with continuous dyspnea. The duration
is relatively small, limiting the use of drugs as needed, unless they are administered pre-emptively
when the trigger is predictable. These findings encourage the improvement of the level of background
dyspnea, or the finding of an alternative measure for EB. Patient-relevant therapeutic targets for the
future evaluation of adequate pharmacological and nonpharmacological management options should
be determined in future studies.
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